Anzalone Christopher Richard bought ARWR
March 13, 2025 · Form 4 insider transaction
Anzalone Christopher Richard bought 340,000 shares of Arrowhead Pharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
340,000
Price
$0.00
Total value
N/A
InsiderAnzalone Christopher Richard
Role—
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateMarch 13, 2025
Filing dateMarch 17, 2025
Shares owned after4,113,802
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Represents performance awards granted on December 22, 2023, and certified on March 12, 2025, upon the achievement of certain performance goals.